scispace - formally typeset
F

Fabien Zoulim

Researcher at French Institute of Health and Medical Research

Publications -  716
Citations -  40988

Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.

Papers
More filters

Case report Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient

TL;DR: The first case of sequential selection of lamivudine and adefovir resistant strains of HBV in a liver transplantation patient is described and the selection of the N236T polymerase mutant was associated with resistance to ADV but remained sensitive to lamivUDine in vitro and in vivo.
Journal ArticleDOI

Hepatitis B virus genetic variability and evolution

TL;DR: Hepatitis B virus has been evolving gradually over a long period of time, resulting in a large amount of genetic diversity, despite the constraints imposed by the complex genetic organization of the viral genome.
Journal ArticleDOI

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

TL;DR: The results suggest that the emergence of the triple mutant may be delayed and associated with viral resistance in patients treated with 3TC+ADV, and provides a rationale for the clinical evaluation of de novo combination therapies.
Journal ArticleDOI

Present and future therapies of hepatitis B: From discovery to cure

TL;DR: The current state of science in HBV therapy is reviewed and new and exciting therapeutic strategies spurred by recent scientific advances are highlighted, bringing us closer to the possibility of a functional cure of chronic HBV infection.
Journal ArticleDOI

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

TL;DR: An international group of experienced hepatologists and virologists conducted a single-day workshop to review the management of patients with chronic hepatitis B receiving treatment with oral nucleosides or nucleotides, recommending monitoring of serum HBV DNA levels to identify outcomes of therapy.